|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF326 |
Gene summary for ZNF326 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF326 | Gene ID | 284695 |
| Gene name | zinc finger protein 326 | |
| Gene Alias | ZAN75 | |
| Cytomap | 1p22.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A0A0MRN4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 284695 | ZNF326 | LZE2T | Human | Esophagus | ESCC | 3.54e-02 | 5.03e-01 | 0.082 |
| 284695 | ZNF326 | LZE4T | Human | Esophagus | ESCC | 2.45e-13 | 5.95e-01 | 0.0811 |
| 284695 | ZNF326 | LZE5T | Human | Esophagus | ESCC | 1.39e-02 | 4.81e-01 | 0.0514 |
| 284695 | ZNF326 | LZE7T | Human | Esophagus | ESCC | 2.92e-06 | 7.54e-01 | 0.0667 |
| 284695 | ZNF326 | LZE8T | Human | Esophagus | ESCC | 7.37e-13 | 2.37e-01 | 0.067 |
| 284695 | ZNF326 | LZE20T | Human | Esophagus | ESCC | 3.14e-13 | 4.28e-01 | 0.0662 |
| 284695 | ZNF326 | LZE24T | Human | Esophagus | ESCC | 1.41e-14 | 5.20e-01 | 0.0596 |
| 284695 | ZNF326 | LZE6T | Human | Esophagus | ESCC | 1.76e-02 | 1.02e-01 | 0.0845 |
| 284695 | ZNF326 | P1T-E | Human | Esophagus | ESCC | 2.96e-08 | 6.65e-01 | 0.0875 |
| 284695 | ZNF326 | P2T-E | Human | Esophagus | ESCC | 1.01e-48 | 1.06e+00 | 0.1177 |
| 284695 | ZNF326 | P4T-E | Human | Esophagus | ESCC | 4.23e-32 | 8.51e-01 | 0.1323 |
| 284695 | ZNF326 | P5T-E | Human | Esophagus | ESCC | 1.25e-24 | 6.96e-01 | 0.1327 |
| 284695 | ZNF326 | P8T-E | Human | Esophagus | ESCC | 1.05e-33 | 6.70e-01 | 0.0889 |
| 284695 | ZNF326 | P9T-E | Human | Esophagus | ESCC | 6.74e-15 | 4.24e-01 | 0.1131 |
| 284695 | ZNF326 | P10T-E | Human | Esophagus | ESCC | 9.61e-55 | 9.80e-01 | 0.116 |
| 284695 | ZNF326 | P11T-E | Human | Esophagus | ESCC | 1.52e-17 | 8.43e-01 | 0.1426 |
| 284695 | ZNF326 | P12T-E | Human | Esophagus | ESCC | 1.20e-91 | 2.15e+00 | 0.1122 |
| 284695 | ZNF326 | P15T-E | Human | Esophagus | ESCC | 5.24e-30 | 7.55e-01 | 0.1149 |
| 284695 | ZNF326 | P16T-E | Human | Esophagus | ESCC | 3.92e-37 | 6.57e-01 | 0.1153 |
| 284695 | ZNF326 | P17T-E | Human | Esophagus | ESCC | 4.11e-09 | 4.36e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
| GO:0043484111 | Esophagus | ESCC | regulation of RNA splicing | 116/8552 | 148/18723 | 3.18e-16 | 2.38e-14 | 116 |
| GO:000635414 | Esophagus | ESCC | DNA-templated transcription, elongation | 76/8552 | 91/18723 | 8.35e-14 | 4.11e-12 | 76 |
| GO:003278412 | Esophagus | ESCC | regulation of DNA-templated transcription, elongation | 45/8552 | 53/18723 | 3.64e-09 | 7.61e-08 | 45 |
| GO:000838022 | Liver | HCC | RNA splicing | 313/7958 | 434/18723 | 1.36e-36 | 1.73e-33 | 313 |
| GO:004348422 | Liver | HCC | regulation of RNA splicing | 113/7958 | 148/18723 | 4.32e-17 | 4.15e-15 | 113 |
| GO:000635411 | Liver | HCC | DNA-templated transcription, elongation | 64/7958 | 91/18723 | 7.00e-08 | 1.44e-06 | 64 |
| GO:0032784 | Liver | HCC | regulation of DNA-templated transcription, elongation | 39/7958 | 53/18723 | 4.34e-06 | 5.53e-05 | 39 |
| GO:00434848 | Lung | IAC | regulation of RNA splicing | 49/2061 | 148/18723 | 4.76e-13 | 7.06e-10 | 49 |
| GO:00083808 | Lung | IAC | RNA splicing | 75/2061 | 434/18723 | 4.89e-05 | 1.12e-03 | 75 |
| GO:004348413 | Lung | AIS | regulation of RNA splicing | 45/1849 | 148/18723 | 2.75e-12 | 2.67e-09 | 45 |
| GO:000838013 | Lung | AIS | RNA splicing | 68/1849 | 434/18723 | 8.50e-05 | 2.11e-03 | 68 |
| GO:000838020 | Oral cavity | OSCC | RNA splicing | 308/7305 | 434/18723 | 2.43e-42 | 7.70e-39 | 308 |
| GO:004348420 | Oral cavity | OSCC | regulation of RNA splicing | 108/7305 | 148/18723 | 4.25e-17 | 3.69e-15 | 108 |
| GO:00063547 | Oral cavity | OSCC | DNA-templated transcription, elongation | 63/7305 | 91/18723 | 4.86e-09 | 1.07e-07 | 63 |
| GO:00327843 | Oral cavity | OSCC | regulation of DNA-templated transcription, elongation | 36/7305 | 53/18723 | 1.89e-05 | 1.83e-04 | 36 |
| GO:000838027 | Skin | AK | RNA splicing | 111/1910 | 434/18723 | 1.85e-20 | 5.49e-17 | 111 |
| GO:004348428 | Skin | AK | regulation of RNA splicing | 54/1910 | 148/18723 | 9.66e-18 | 9.53e-15 | 54 |
| GO:00063549 | Skin | AK | DNA-templated transcription, elongation | 25/1910 | 91/18723 | 2.82e-06 | 7.60e-05 | 25 |
| GO:00327845 | Skin | AK | regulation of DNA-templated transcription, elongation | 16/1910 | 53/18723 | 4.87e-05 | 7.59e-04 | 16 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF326 | deletion | Frame_Shift_Del | c.1325_1358delNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN | p.Arg443IlefsTer4 | p.R443Ifs*4 | Q5BKZ1 | protein_coding | TCGA-A2-A04T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |||
| ZNF326 | insertion | Frame_Shift_Ins | novel | c.573_574insATCTTTTATGTTTTATCTGTTTATCCTTCTA | p.Ala192IlefsTer28 | p.A192Ifs*28 | Q5BKZ1 | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | ||
| ZNF326 | insertion | In_Frame_Ins | novel | c.864_865insATC | p.Ala288_Arg289insIle | p.A288_R289insI | Q5BKZ1 | protein_coding | TCGA-A7-A26I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | ||
| ZNF326 | insertion | Frame_Shift_Ins | novel | c.1602_1603insGTAAAAGATGTGGTGACATTATTCACAGAACAGGTAA | p.Ile535ValfsTer51 | p.I535Vfs*51 | Q5BKZ1 | protein_coding | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| ZNF326 | SNV | Missense_Mutation | novel | c.1566G>T | p.Glu522Asp | p.E522D | Q5BKZ1 | protein_coding | tolerated_low_confidence(0.6) | benign(0.222) | TCGA-MU-A5YI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| ZNF326 | SNV | Missense_Mutation | c.1001C>G | p.Ser334Cys | p.S334C | Q5BKZ1 | protein_coding | deleterious(0.03) | possibly_damaging(0.526) | TCGA-Q1-A73P-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZNF326 | SNV | Missense_Mutation | rs773591916 | c.407N>G | p.Tyr136Cys | p.Y136C | Q5BKZ1 | protein_coding | deleterious(0.01) | probably_damaging(0.956) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF326 | SNV | Missense_Mutation | c.873G>T | p.Glu291Asp | p.E291D | Q5BKZ1 | protein_coding | tolerated(0.22) | probably_damaging(0.978) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF326 | SNV | Missense_Mutation | rs201031234 | c.329G>A | p.Arg110Gln | p.R110Q | Q5BKZ1 | protein_coding | tolerated(0.14) | possibly_damaging(0.704) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF326 | SNV | Missense_Mutation | c.1680N>T | p.Glu560Asp | p.E560D | Q5BKZ1 | protein_coding | tolerated_low_confidence(0.52) | benign(0.003) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |